Journal Article

DKFZ-2018-00462

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png E-cadherin breast tumor expression, risk factors and survival: Pooled analysis of 5,933 cases from 12 studies in the Breast Cancer Association Consortium.

Horne, H. N. ; Oh, H. ; Sherman, M. E. ; Palakal, M. ; Hewitt, S. M. ; Schmidt, M. K. ; Milne, R. L. ; Hardisson, D. ; Benitez, J. ; Blomqvist, C. ; Bolla, M. K. ; Brenner, H.DKFZ* ; Chang-Claude, J.DKFZ* ; Cora, R. ; Couch, F. J. ; Cuk, K.DKFZ* ; Devilee, P. ; Easton, D. F. ; Eccles, D. M. ; Eilber, U.DKFZ* ; Hartikainen, J. M. ; Heikkilä, P. ; Holleczek, B. ; Hooning, M. J. ; Jones, M. ; Keeman, R. ; Mannermaa, A. ; Martens, J. W. M. ; Muranen, T. A. ; Nevanlinna, H. ; Olson, J. E. ; Orr, N. ; Perez, J. I. A. ; Pharoah, P. D. P. ; Ruddy, K. J. ; Saum, K.-U.DKFZ* ; Schoemaker, M. J. ; Seynaeve, C. ; Sironen, R. ; Smit, V. T. H. B. M. ; Swerdlow, A. J. ; Tengström, M. ; Thomas, A. S. ; Timmermans, A. M. ; Tollenaar, R. A. E. M. ; Troester, M. A. ; van Asperen, C. J. ; van Deurzen, C. H. M. ; Van Leeuwen, F. F. ; Van't Veer, L. J. ; García-Closas, M. ; Figueroa, J. D.

2018
Nature Publishing Group London

This record in other databases:  

Please use a persistent id in citations: doi:10.1038/s41598-018-23733-4

Abstract: E-cadherin (CDH1) is a putative tumor suppressor gene implicated in breast carcinogenesis. Yet, whether risk factors or survival differ by E-cadherin tumor expression is unclear. We evaluated E-cadherin tumor immunohistochemistry expression using tissue microarrays of 5,933 female invasive breast cancers from 12 studies from the Breast Cancer Consortium. H-scores were calculated and case-case odds ratios (OR) and 95% confidence intervals (CIs) were estimated using logistic regression. Survival analyses were performed using Cox regression models. All analyses were stratified by estrogen receptor (ER) status and histologic subtype. E-cadherin low cases (N = 1191, 20%) were more frequently of lobular histology, low grade, >2 cm, and HER2-negative. Loss of E-cadherin expression (score < 100) was associated with menopausal hormone use among ER-positive tumors (ever compared to never users, OR = 1.24, 95% CI = 0.97-1.59), which was stronger when we evaluated complete loss of E-cadherin (i.e. H-score = 0), OR = 1.57, 95% CI = 1.06-2.33. Breast cancer specific mortality was unrelated to E-cadherin expression in multivariable models. E-cadherin low expression is associated with lobular histology, tumor characteristics and menopausal hormone use, with no evidence of an association with breast cancer specific survival. These data support loss of E-cadherin expression as an important marker of tumor subtypes.

---

Contributing Institute(s):

1. C070 Klinische Epidemiologie und Alternf. (C070)
2. Präventive Onkologie (G110)
3. C020 Epidemiologie von Krebs (C020)
4. DKTK Heidelberg (L101)

Research Program(s):

1. 313 - Cancer risk factors and prevention (POF3-313) (POF3-313)

Appears in the scientific report 2018

---

Database coverage:
; ; ; BIOSIS Previews ; Current Contents - Physical, Chemical and Earth Sciences ; DOAJ Seal ; IF >= 5 ; JCR ; NCBI Molecular Biology Database ; SCOPUS ; Science Citation Index ; Science Citation Index Expanded ; Thomson Reuters Master Journal List ; Web of Science Core Collection ; Zoological Record

---